FUROXONE
LOE ApproachingNDAORALTABLET
Approved
Mar 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUROXONE is an oral small-molecule tablet approved in 1961 by Takeda with an unknown mechanism of action and indication profile. The drug's exact therapeutic target and patient population remain undocumented in available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting team focus may shift to cost management or lifecycle extensions rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect FUROXONE's mature, declining lifecycle stage with minimal hiring for brand expansion. Career opportunities are concentrated in defensive commercial roles focused on market maintenance and generic transition management rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on FUROXONE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.